Lipid-lowering drugs associated with decrease in glycemic control in type 2 diabetes

EASD: they compared HbA1c levels during 18 months of follow-up in subjects with or without lipid drugs
EASD: they compared HbA1c levels during 18 months of follow-up in subjects with or without lipid drugs